The Merck Index, 11th edition, pp. 373, 1430, and 1504, 1989. |
Osband et al. "Problems in the invetigational study and clinical use of cancer immunotherapy" Immunotherapy, p. 1930-195, 1990. |
Chaterjee et al. "Idiotype antibody immunotherapy of cancer" Cancer Immunol. Immunother. vol. 38, pp. 75-82, 1994. |
Mallmann et al, "Effect of Tamoxifen and high-does medroxyprogesterone acetate (MPA) on cell mediated immune functions in breast cancer patients" Meth. Find. Exp. Clin. Pharmocol. vol. 12, No. 10, pp. 699-706, 1990. |
Berry et al. "Modulation of natural killer cell activity by Tamoxifen in stage I post-menopausal breast cancer" Eur. J. Cancer Clin. Oncol., vol. 23, No. 5, pp. 517-520, 1987. |
Kangas et al, "Additive and synergistic effects of a novel antiestrogen, toremifene (Fc-1157a), and human interferons on estrogen responsive MCF-7 cells in vitro" Med. Biol. vol. 63, pp. 187-190, 1985. |
Robertson et al, "Biology and clinical relevance of human natural killer cells" Blood, vol. 76, No. 12, pp. 2421-2438, 1990. |
Michael Andersson et al., "Incidence of New Primary Cancers After Adjuvant Tamoxifen Therapy and Radiotherapy for Early Breast Cancer", J. Natl. Cancer Institute, vol. 83, No. 14, Jul. 17, 1991. |
R.I. Freshney, "B. Monolayer Cultures", Short Term Culture of Human Tumours. Techniques and Clinical Applications, PP. Dendy, ed. Academic Press, London, 1976. |
Shigeyoshi Fujimoto et al., "Development of Specific Immunotherapy for Cancer", (translation from abstract), Human Cell, 5, 247-55, 1992. |
Tenho Hietanen et al., "High Dose Toremifene (240 mg daily) is Effective as First Line Hormonal Treatment in Advanced Breast Cancer -An Ongoing Phase II Multicenter Finnish-Latvian Cooperative Study", Breast Cancer Research and Treatment, 16, S-37-40, 1990. |
Steven A. Rosenberg, M.D. et al., "A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High Dose Interleukin-2 Alone", New England Journal of Medicine, vol. 316, No. 15, Apr. 1987, pp. 889-897. |
Ichiro Yoshino et al., "Cytolytic Potential of Peripheral Blood T-Lymphocytes Following Adoptive Immunotherapy with Lymphokine-Activated Killer Cells and Low-Dose Interleukin-2", Cancer Research, 51, 1494-1498, Mar. 1, 1991. |
Herbert C. Hoover, Jr. et al., "Adjuvant Active Specific Immunotherapy for Human Colorectal Cancer: 6.5 Year Median Follow-up of a Phase III Prospectively Randomized Trial", Journal of Clinical Oncology, vol. 11, No. 3, (Mar.), 1993: pp. 390-399. |
Alfred E. Chang et al., "Clinical Observations on Adoptive Immunotherapy with Vaccine-primed T-Lymphocytes Secondarily Sensitized to Tumor in Vitro", Cancer Research, 53, 1043-1050, Mar. 1, 1993. |
Philip O. Livingston, "Construction of Cancer Vaccines with Carbohydrate and Protein (Peptide) Tumor Antigens", Current Opinion in Immunology, 4,5, 624-9, 1992. |
Masashi Komatsumoto et al., "The Improved Effects of Specific Active Immunotherapy on a Rat Fibrosarcoma by Antitumor Drugs", Cancer Immunology Immunotherapy, 33, 279-284, 1991. |
Kroum T. Kassabov et al., "Inhibition of Spontaneous Pulmonary Metastases of Lewis Lung Carcinoma by Oral Treatment with Respivax and Broncho-Vaxom", Cancer Immunology Immunotherapy, 33, 307-313, 1991. |
Mary Nel Saarloos et al., "Effects of Cancer Immunotherapy with Indomethacin and Interleukin-2 on Murine Hemopoietic Stem Cells", Cancer Research, 52, 6452-6462, Dec. 1, 1992. |
Hisashi Aso et al., "Impaired NK Response of Cancer Patients to IFN-.alpha. but Not to IL-2: Correlation with Serum Immunosuppressive Acidic Protein (IAP) and Role of Suppressor Macrophage", Microbiological Immunology, vol. 36, (10), 1087-1097, 1992. |
Teruhiro Utsugi et al., "Comparative Efficacy of Liposomes Containing Synthetic Bacterial Cell Wall Analogues for Tumoricidal Activation of Monocytes and Macrophages", Cancer Immunology Immunotherapy, 33, 287-292, 1991. |
Mark R. Albertini et al., "Influence of Estradiol and Tamoxifen on Susceptibility of Human Breast Cancer Cell Lines to Lysis by Lymphokine-Activated Killer Cells", Journal of Immunotherapy, vol. 11, No. 1, pp. 30-39, 1992. |
Benjamin Kim, M.D., et al., "Tamoxifen Potentiates in Vivo Antitumor Activity of Interleukin-2", Surgery, vol. 108, No. 2, pp. 139-145, Aug. 1990. |
Stephen E. Ettinghausen et al., "Recombinant Interleukin 2 Stimulates in Vivo Proliferation of Adoptively Transferred Lymphokine-Activated Killer (LAK) Cells", The Journal of Immunology, Nov. 1985, vol. 135, No. 5, pp. 3623-3635. |
John Berry et al., "Modulation of Natural Killer Cell Activity By Tamoxifen in Stage I Post-Menopausal Breast Cancer", Eur. J. Cancer Clin Oncol., vol. 23, No. 5, pp. 517-520, 1987. |
Bluma G. Brenner et al., "The Relationship of Chemotherapuetic and Endocrine Intervention on Natural Killer Cell Activity in Human Breast Cancer", Cancer, 68: pp. 482-488. |
E. Robinson et al., "In vivo modualation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer", Cancer Immunol Immunother, (1993) 37: 209-212. |